HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio

European Patent Allowed for Quantification by an ECG of Key Heart Measures using AI

Heart Test Laboratories, an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announces that it has been issued a notice of patent allowance from the European Patent Office.

AiThority Interview Insights: AiThority Interview with Bret Greenstein, Partner, Data & AI at PwC

To date, HeartSciences has been granted or allowed 41 patents including 9 in the United States. Issued international patents are across key countries including China, Brazil, Canada, India, South Korea, Mexico, and key European markets such as Germany, France, UK, Italy and the Netherlands.

The European Patent Office (EPO) has 39 European member countries, and the patent allowance covers quantification by an ECG of key echocardiographic measures of heart function using AI methods which has never been possible with a conventional ECG.

Read More about AiThority Interview: AiThority Interview with Rebecca Jones, General Manager at Mosaicx

Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “Millions of ECG’s are performed worldwide every week and the ECG is by far the most ubiquitous cardiac test. The addition of cardiac dysfunction detection to the ECG is expected to provide significant benefit to healthcare providers and health systems around the world. Cardiovascular disease continues to rise and accounts for 20.5 million deaths, an estimated 1 in 3 of all deaths worldwide. HeartSciences MyoVista® could play a significant role in heart health screening worldwide.”

Mr. Simpson continued, “AI continues to revolutionize medical devices and health systems and we are delighted to add another AI patent for an ECG. Given the huge market opportunity, protection of our intellectual property and patents in major markets is core to the Company as it provides intrinsic value to HeartSciences and would be expected to be a source of major competitive advantage as we move toward commercialization. This latest patent further expands our international coverage and is the latest addition to our extensive patent portfolio.”

 Latest AiThority Interview Insights : AiThority Interview with Dan O’Connell, Chief AI & Strategy Officer at Dialpad

 [To share your insights with us, please write to sghosh@martechseries.com]